AstraZeneca’s (AZN) “Sell” Rating Reiterated at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “sell” rating reiterated by Deutsche Bank Aktiengesellschaft in a report issued on Tuesday,Digital Look reports. They presently have a £115 price objective on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective suggests a potential downside of 11.93% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. Jefferies Financial Group reissued a “buy” rating and set a £180 price objective on shares of AstraZeneca in a report on Friday, June 26th. Berenberg Bank reaffirmed a “buy” rating and issued a £160 target price on shares of AstraZeneca in a report on Tuesday. Finally, Citigroup increased their target price on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research report on Tuesday. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus price target of £153.

Get AstraZeneca alerts:

View Our Latest Stock Analysis on AstraZeneca

AstraZeneca Price Performance

Shares of LON AZN traded up GBX 170 during midday trading on Tuesday, reaching £130.58. 31,164,986 shares of the company were exchanged, compared to its average volume of 30,378,725. The stock’s 50-day moving average price is £134.89 and its 200-day moving average price is £140.60. The stock has a market cap of £202.51 billion, a P/E ratio of 19.67, a PEG ratio of 0.86 and a beta of 0.23. AstraZeneca has a one year low of £107.44 and a one year high of £157.32. The company has a quick ratio of 0.59, a current ratio of 0.91 and a debt-to-equity ratio of 71.66.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Featured Articles

• Five stocks we like better than AstraZeneca
• Amkor Sells Off After Earnings—Why Weak Guidance Isn’t the Real Story
• 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys?
• Whirlpool’s Report May Show How Frozen the Housing Market Really Is
• 3 Stocks Standing Out and 2 Losing Momentum as the Tech Rally Cracks

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.